Surgical sepsis: prevention and therapy

Author(s):  
QM Nunes ◽  
CV Soong ◽  
BJ Rowlands
Pflege ◽  
2000 ◽  
Vol 13 (5) ◽  
pp. 297-305 ◽  
Author(s):  
Stefan Roales-Welsch ◽  
Antaszek ◽  
Hense ◽  
Pfeiffer ◽  
Freyenhagen ◽  
...  

In dieser Studie zur Qualitätssicherung in der Prophylaxe und Therapie des Dekubitus durch Auflagedruckmessungen bei Probanden auf sechs Weichlagerungs- und fünf Wechseldrucksystemen war die Zielsetzung, eine Ist-Analyse der am Klinikum eingesetzten Antidekubitushilfsmittel durchzuführen. Außerdem galt es herauszufinden, ob die angewandte Methode der pneumatischen Druckmessung mit Probanden auch im Versorgungsalltag verwendbar ist. Können verlässliche und valide Messdaten erwartet werden, wenn man bei betroffenen Patienten Messungen durchführt? Zur Beantwortung dieser Fragen wurden bei 23/19 Probanden, auch in Seitenlage, durch das Platzieren von Messmatten zwischen Körper und unterschiedliche Antidekubitussysteme Messungen durchgeführt. Bei den Weichlagerungssystemen kann an allen Messorten eine signifikante Druckreduzierung (p < 0,05), am Os coccygis eine hochsignifikante Druckreduzierung (p < 0,01) nachgewiesen werden. Bei den Wechseldrucksystemen liegt der Mittelwert der maximalen Druckbelastung über 12 min bei unterschiedlicher Amplitude (75,47 mmHg–5 mmHg) und verschiedener Frequenz (1,5 min–10 min) zwischen 56,39 mmHg und 38,94 mmHg.


2018 ◽  
Vol 19 (11) ◽  
pp. 1256-1264 ◽  
Author(s):  
Joël Pincemail ◽  
Jean-Olivier Defraigne ◽  
Audrey Courtois ◽  
Adelin Albert ◽  
Jean-Paul Cheramy-Bien ◽  
...  

2020 ◽  
Vol 11 (2) ◽  
pp. 145-153 ◽  
Author(s):  
Rosalba Leuci ◽  
Leonardo Brunetti ◽  
Antonio Laghezza ◽  
Paolo Tortorella ◽  
Fulvio Loiodice ◽  
...  

In the near future, it is expected that the prevalence of illnesses related to the increasing life expectancies and quality of life, such as neurodegenerative diseases and cardiovascular diseases related to metabolic disorders, will soar to unprecedented levels, leading to high socioeconomic costs. To address this rising threat, natural products are emerging as a novel strategy for the prevention and therapy of these ages- and lifestyle-related diseases, thanks to their high marketability and few side effects. In this patent review, we summarize selected patents for food supplements, functional and fortified foods, filed from 2016 to 2019, categorizing them based on the biological activity of their components.


2021 ◽  
Vol 22 (15) ◽  
pp. 8223
Author(s):  
Violetta Krajka-Kuźniak ◽  
Wanda Baer-Dubowska

Nrf2 (nuclear factor erythroid 2-related factor 2) and NF-κB (nuclear factor–kappa B) signaling pathways play a central role in suppressing or inducing inflammation and angiogenesis processes. Therefore, they are involved in many steps of carcinogenesis through cooperation with multiple signaling molecules and pathways. Targeting both transcription factors simultaneously may be considered an equally important strategy for cancer chemoprevention and therapy. Several hundreds of phytochemicals, mainly edible plant and vegetable components, were shown to activate Nrf2 and mediate antioxidant response. A similar number of phytochemicals was revealed to affect NF-κB. While activation of Nrf2 and inhibition of NF-κB may protect normal cells against cancer initiation and promotion, enhanced expression and activation in cancer cells may lead to resistance to conventional chemo- or radiotherapy. Most phytochemicals, through different mechanisms, activate Nrf2, but others, such as luteolin, can act as inhibitors of both Nrf2 and NF-κB. Despite many experimental data confirming the above mechanisms currently, limited evidence exists demonstrating such activity in humans. Combinations of phytochemicals resembling that in a natural food matrix but allowing higher concentrations may improve their modulating effect on Nrf2 and NF-κB and ultimately cancer prevention and therapy. This review presents the current knowledge on the effect of selected phytochemicals and their combinations on Nrf2 and NF-κB activities in the above context.


2020 ◽  
Vol 21 (18) ◽  
pp. 6759 ◽  
Author(s):  
Mikhail Korokin ◽  
Vladimir Gureev ◽  
Oleg Gudyrev ◽  
Ivan Golubev ◽  
Liliya Korokina ◽  
...  

Preeclampsia is a severe disease of late pregnancy. Etiological factors and a pathogenetic pattern of events still require significant clarification, but it is now recognized that a large role is played by placentation disorders and emerging endothelial dysfunction. The administration of short-chain peptides mimicking the spatial structure of the B erythropoietin chain may become one of the directions of searching for new drugs for preeclampsia prevention and therapy. Simulation of ADMA-like preeclampsia in Wistar rats was performed by the administration of a non-selective NOS blocker L-NAME from the 14th to 20th day of pregnancy. The administration of the pHBSP at the doses of 10 µg/kg and 250 µg/kg corrected the established morphofunctional disorders. The greatest effect was observed at a dose of 250 µg/kg. There was a decrease in systolic and diastolic blood pressure by 31.2 and 32.8%, respectively (p < 0.0001), a decrease in the coefficient of endothelial dysfunction by 48.6% (p = 0.0006), placental microcirculation increased by 82.8% (p < 0.0001), the NOx concentration was increased by 42,6% (p = 0.0003), the greater omentum edema decreased by 11.7% (p = 0.0005) and proteinuria decreased by 76.1% (p < 0.0002). In addition, there was an improvement in the morphological pattern of the fetoplacental complex and the ratio of BAX to Bcl-2 expression which characterizes the apoptotic orientation of the cells.


Sign in / Sign up

Export Citation Format

Share Document